Måndag 15 December | 12:19:40 Europe / Stockholm

Svenska | English

Crinetics Pharmaceuticals Inc.

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Filter

År

Typ

Språk

Rensa

2025-12-11 22:05:00 Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) 49,31 USD | +2,60%

2025-12-10 22:34:46 Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 48,06 USD | +0,33%

2025-12-03 14:00:00 Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors 46,98 USD | +4,38%

2025-11-20 22:05:00 Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome 41,97 USD | -2,17%

2025-11-10 22:28:41 Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 41,45 USD | +3,63%

2025-10-23 14:00:00 Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting 40,08 USD | -0,87%

2025-10-10 22:41:07 Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 44,93 USD | -1,81%

2025-10-06 22:05:00 Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 41,68 USD | +2,01%

2025-09-25 23:30:31 Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly 35,89 USD | +2,02%

2025-09-10 22:30:48 Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 35,00 USD | -4,11%

2025-08-21 14:45:00 Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH) 29,40 USD | +1,07%

2025-08-11 22:05:00 Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 27,38 USD | +1,97%

2025-07-13 23:45:00 Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025

2025-07-11 14:00:00 Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025 31,93 USD | -0,19%

2025-07-10 22:28:57 Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 31,99 USD | -1,05%

2025-06-30 22:05:00 Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline 28,76 USD | -4,01%

2025-06-10 22:29:30 Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 33,08 USD | +2,48%

2025-05-23 14:00:00 Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025 29,76 USD | -1,16%

2025-05-15 22:05:00 Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025

2025-05-08 22:05:00 Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update 32,70 USD | +4,17%

2025-04-11 14:00:00 Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 29,11 USD | +8,42%

2025-04-10 23:04:07 Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 26,85 USD | -2,93%

2025-03-27 21:05:00 Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly 34,90 USD | +1,13%

2025-03-10 21:36:21 Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 33,75 USD | +1,41%

2025-02-24 14:30:00 Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer 34,62 USD | -7,58%

2025-02-20 22:05:00 Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences 36,86 USD | +0,71%

2025-02-10 22:44:27 Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 36,53 USD | -1,22%

2025-02-06 22:35:20 Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 38,71 USD | -1,50%

2025-01-10 23:15:15 Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 40,59 USD | -16,31%

2025-01-10 13:00:00 Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) 40,59 USD | -16,31%

2025-01-06 14:00:00 Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 50,49 USD | -5,00%

2024-12-11 02:44:38 Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 60,15 USD | +5,21%

2024-12-09 14:00:00 Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly 56,62 USD | -3,82%

2024-11-15 15:00:00 Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences 54,72 USD | -8,28%

2024-11-14 22:05:00 UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting 59,66 USD | +1,26%

2024-11-12 22:07:00 Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting 58,78 USD | -2,05%

2024-11-12 22:05:00 Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update 58,78 USD | -2,05%

2024-11-11 22:05:00 Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 60,01 USD | -1,12%

2024-10-16 14:00:00 Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024 58,86 USD | +2,19%

2024-10-10 22:40:28 Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 51,78 USD | +2,13%

2024-10-09 05:55:11 Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock 50,70 USD | -1,93%

2024-10-08 22:01:51 Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock 51,70 USD | -0,12%

2024-09-26 22:05:00 Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly 50,58 USD | +0,26%

2024-09-10 22:40:25 Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 50,40 USD | -3,52%

2024-08-29 22:05:00 Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences 52,70 USD | -3,12%

2024-08-12 22:05:00 Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 49,57 USD | +4,05%

2024-08-08 14:30:00 Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges 50,74 USD | +5,05%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Crinetics Pharmaceuticals Inc.

Vem äger bolaget?

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden